Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-005554-23
    Sponsor's Protocol Code Number:1199-0378
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-11-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2020-005554-23
    A.3Full title of the trial
    An open-label trial of the long-term safety and tolerability of nintedanib per os, on top of standard of care, over at least 2 years, in children and adolescents with clinically significant fibrosing Interstitial Lung Disease (InPedILD™-ON)
    Etude en ouvert sur la sécurité et la tolérance à long terme du nintédanib per os, en plus des soins standards, sur une période d’au moins 2 ans, chez des enfants et des adolescents avec une pneumopathie interstitielle fibrosante cliniquement significative (InPedILDTM-ON).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD™-ON)
    Une étude pour évaluer la sécurité à long terme du nintédanib chez des enfants et des adolescents avec une
    pneumopathie interstitielle (InPedILDTM-ON).
    A.3.2Name or abbreviated title of the trial where available
    InPedILD™-ON
    InPedILD™-ON
    A.4.1Sponsor's protocol code number1199-0378
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/150/2019
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBoehringer Ingelheim France
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBoehringer Ingelheim France
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBoehringer Ingelheim Pharma GmbH&Co KG
    B.5.2Functional name of contact pointCT Disclosure & Data Transparency
    B.5.3 Address:
    B.5.3.1Street AddressBinger Strasse 173
    B.5.3.2Town/ cityIngelheim am Rhein
    B.5.3.3Post code55216
    B.5.3.4CountryGermany
    B.5.4Telephone number+498002430127
    B.5.5Fax number+498008217119
    B.5.6E-mailclintriage.rdg@boehringer-ingelheim.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ofev®
    D.2.1.1.2Name of the Marketing Authorisation holderBoehringer Ingelheim International GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNintedanib 150 mg capsules
    D.3.2Product code Nintedanib
    D.3.4Pharmaceutical form Capsule, soft
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNintedanib
    D.3.9.1CAS number 656247-17-5
    D.3.9.3Other descriptive nameNINTEDANIB
    D.3.9.4EV Substance CodeSUB120728
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ofev®
    D.2.1.1.2Name of the Marketing Authorisation holderBoehringer Ingelheim International GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNintedanib 100 mg capsules
    D.3.2Product code Nintedanib
    D.3.4Pharmaceutical form Capsule, soft
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNintedanib
    D.3.9.1CAS number 656247-17-5
    D.3.9.3Other descriptive nameNINTEDANIB
    D.3.9.4EV Substance CodeSUB120728
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNintedanib 25 mg capsules
    D.3.2Product code Nintedanib
    D.3.4Pharmaceutical form Capsule, soft
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNintedanib
    D.3.9.1CAS number 656247-17-5
    D.3.9.3Other descriptive nameNINTEDANIB
    D.3.9.4EV Substance CodeSUB120728
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Interstitial Lung Disease
    Pneumopathie Interstitielle Fibrosante
    E.1.1.1Medical condition in easily understood language
    Interstitial Lung Disease
    Pneumopathie Interstitielle Fibrosante
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10066393
    E.1.2Term Respiratory bronchiolitis-associated interstitial lung disease
    E.1.2System Organ Class 100000004855
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The trial will assess the safety and tolerability of long-term treatment with nintedanib in pediatric patients with clinically significant fibrosing ILD.
    The primary objective is to estimate the incidence of treatment emergent adverse events over the whole trial.
    L’essai évaluera la sécurité et la tolérance du traitement à long terme par le nintédanib chez les patients pédiatriques atteints de pneumopathie interstitielle fibrosante cliniquement significative.
    L’objectif principal est d’estimer l'incidence des événements indésirables survenus pendant le traitement sur l’ensemble de l'essai.
    E.2.2Secondary objectives of the trial
    Not applicable
    Non applicable
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    HRCT substudy:
    only at selected sites in the United States (US) for patients who already participated in the similar substudy in the parent trial
    Details of the planned HRCT analyses and endpoints will be described in a specific Statistical Analysis Plan (SAP) for the substudy and are considered exploratory.
    Sous-étude HRCT : uniquement dans des sites sélectionnés aux États-Unis pour les patients qui ont déjà participé à la sous-étude similaire dans l'essai parent.
    Les détails des analyses HRCT et des critères d'évaluation prévus seront décrits dans un plan d'analyse statistique (SAP) spécifique pour la sous-étude et sont considérés comme exploratoires.
    E.3Principal inclusion criteria
    For new patients:

    1. Children and adolescents 6 to 17 years old at Visit 2.
    2. Signed and dated written informed consent and assent, where applicable, in accordance with ICH-GCP and local legislation prior to admission to the trial.
    3. Male or female patients. Female of childbearing potential (WOCBP1) must confirm that sexual abstinence is standard practice and will be continued until 3 months after last drug intake, or be ready and able to use a highly effective method of birth control per ICH M3 (R2) that results in a low failure rate of less than 1% per year when used consistently and correctly, in combination with one barrier method, from 28 days prior to initiation of study treatment, during treatment and until 3 months after last drug intake. Sexual abstinence is defined as abstinence from any sexual act that may result in pregnancy.
    4. Patients with evidence of fibrosing ILD on HRCT within 12 months of Visit 1 as assessed by the investigator and confirmed by central review.
    5. Patients with FVC % predicted ≥25% at Visit 2.
    6. Patients with clinically significant disease at Visit 2, as assessed by the investigator based on any of the following:
    - Fan score ≥3, or
    - Documented evidence of clinical progression over time based on either
    o a 5-10% relative decline in FVC% predicted accompanied by worsening symptoms, or
    o a ≥10% relative decline in FVC % predicted, or
    o increased fibrosis on HRCT, or
    o other measures of clinical worsening attributed to progressive lung disease

    For roll-over patients from the InPedILD™ study:

    Only criteria 2 and 3 listed for new patients are applicable with the following additional inclusion criterion:
    7. Patients who completed the InPedILD™ trial as planned and who did not permanently prematurely discontinue study treatment.

    For patients who discontinued treatment permanently in 1199-0337 but are potentially eligible:

    Criteria for new patients are applicable except criteria 4, and 6
    Pour les nouveaux patients :
    1.Enfants et adolescents âgés entre 6 et 17 ans à la visite 2.
    2.Signature d’un formulaire de consentement éclairé et d’un assentiment (si applicable) conformément aux Bonnes Pratiques Cliniques (ICH-GCP) et à la législation locale avant toute procédure de l’étude.
    3.Patients masculins ou féminins. Les filles en âge de procréer doivent confirmer que l’abstinence sexuelle fait partie de leur pratique courante et qu’elle sera maintenue jusqu’à 3 mois après la dernière prise de traitement à l’étude ou être prêtes et capables d’utiliser une méthode de contraception très efficace conforme aux ICH M3 (R2). Cette dernière se traduit par un faible taux d’échec (moins de 1% par an) lorsqu’elle est utilisée de manière adéquate et correcte, en plus d’une méthode barrière, et ceci 28 jours avant la prise initiale du traitement à l’étude, durant la période de traitement à l’étude et jusqu’à 3 mois après la dernière prise. L’abstinence sexuelle est définie comme l’abstinence de tout acte sexuel pouvant entraîner une grossesse.
    4.Patients présentant des signes de pneumopathie interstitielle fibrosante sur une tomodensitométrie thoracique à haute résolution (TDM-HR) dans les 12 mois précédant la visite de sélection (visite 1), tels qu’évalués par l’investigateur et confirmés par revue centralisée.
    5.Capacité vitale forcée (CVF) ≥ 25 % de la valeur prédite à la visite 2.
    6.Patients présentant une maladie cliniquement significative à la visite 2, telle qu’évaluée par l’investigateur et basée sur l’un des éléments suivants :
    - un score de Fan ≥ 3 ,
    - ou une preuve documentée de la progression clinique de la maladie dans le temps tel que /
    *un déclin relatif entre 5 et 10 % de la CVF exprimée en % de la valeur prédite accompagné d’une aggravation des symptômes, ou
    *un déclin relatif ≥ 10 % de la CVF exprimée en % de la valeur prédite, ou
    *une fibrose aggravée sur la TDM-HR, ou
    *d’autres mesures d’aggravation clinique attribuées à une maladie pulmonaire progressive.

    Pour les patients ayant participé à l’essai InPedILD™ :
    Seuls les critères 2 et 3 pour les nouveaux patients sont applicables avec le critère d'inclusion supplémentaire suivant :
    7. Les patients qui ont terminé l'essai InPedILD™ comme prévu et n'ont pas définitivement interrompu de façon prématurée le traitement de l'étude.

    Pour les patients qui ont arrêté définitivement le traitement dans l’essai InPedILD™ mais qui sont potentiellement éligibles :
    Les critères pour les nouveaux patients sont applicables à l'exception des critères 4 et 6.
    E.4Principal exclusion criteria
    For new patients:
    1. AST and/or ALT >1.5 x ULN at Visit 1.
    2. Bilirubin >1.5 x ULN at Visit 1.
    3. eGFR <30 mL/min calculated by Schwartz formula at Visit 1
    4. Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic impairment) at Visit 1.
    5. Other investigational therapy received within 1 month or 5 half-lives (whichever is shorter but ≥1 week) prior to Visit 2 except investigational therapy received in InPedILD™ trial.
    6. Significant pulmonary arterial hypertension (PAH) defined by any of the following:
    a. Previous clinical or echocardiographic evidence of significant right heart failure
    b. History of right heart catheterization showing a cardiac index ≤2 l/min/m²
    c. PAH requiring parenteral therapy with epoprostenol/treprostinil
    7. In the opinion of the Investigator, other clinically significant pulmonary abnormalities.
    8. Cardiovascular diseases, any of the following:
    a. Severe hypertension, uncontrolled under treatment, within 6 months of Visit 1.
    Uncontrolled hypertension is defined as
    i. In children 6 to ≤12 years old: ≥95th percentile + 12 mm Hg or ≥140/90 mm Hg
    (whichever is lower) (systolic or diastolic blood pressure equal to or greater than
    the calculated target value) (please refer to Appendix 10.5)
    ii. In adolescents 13 to 17 years old: systolic blood pressure ≥140 mm Hg or
    diastolic blood pressure ≥90 mm Hg (please refer to Appendix 10.5)
    b. Myocardial infarction within 6 months of Visit 1
    c. Unstable cardiac angina within 6 months of Visit 1
    9. Bleeding risk, any of the following:
    a. Known genetic predisposition to bleeding
    b. Patients who require
    i. Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin)
    ii. High dose antiplatelet therapy
    c. History of haemorrhagic central nervous system (CNS) event within 12 months of Visit 1
    d. Any of the following within 3 months of Visit 1:
    i. Haemoptysis or haematuria
    ii. Active gastro-intestinal (GI) bleeding or GI – ulcers
    iii. Major injury or surgery (investigator’s judgment)
    e. Any of the following coagulation parameters at Visit 1:
    i. International normalized ratio (INR) >2
    ii. Prolongation of prothrombin time (PT) by >1.5 x ULN
    iii. Prolongation of activated partial thromboplastin time (aPTT) by >1.5 x ULN
    10. History of thrombotic event (including stroke and transient ischemic attack) within 12 months of Visit 1.
    11. Known hypersensitivity to the trial medication or its components (i.e. soya lecithin).
    12. Patients with documented allergy to peanut or soya.
    13. Other disease that may interfere with testing procedures or in the judgment of the investigator may interfere with trial participation or may put the patient at risk when participating in this trial.
    14. Life expectancy for any concomitant disease other than ILD <2.5 years (investigator assessment).
    15. Female patients who are pregnant, nursing, or who plan to become pregnant while in the trial.
    16. Patients not able or willing to adhere to trial procedures, including intake of study medication.
    17. Patients who must or wish to take any drug considered likely to interfere with the safe conduct of the trial according to investigator’s benefit-risk assessment for the individual patient
    18. Patients with any diagnosed growth disorder such as growth hormone deficiency or any genetic disorder that is associated with short stature (e.g. Turner Syndrome, Noonan Syndrome, Russell-Silver Syndrome) and/or treatment with growth hormone therapy
    within 6 months before Visit 2. Patients with short stature considered by the investigator to be due to glucocorticoid therapy may be included.
    19. Patients <13.5 kg of weight at Visit 1 (same threshold to be used for male and female patients).

    For roll-over patients from the InPedILD™ study:

    Only criteria 11, 12, 13, 15, 16, 17 and 19, listed for new patients are applicable with the following additional exclusion criterion:

    20. Patient not compliant in parent trial (InPedILD™), with trial medication or trial visits, according to investigator’s judgement.

    Roll-over patients may qualify for participation even though other exclusion criteria may have been met during the participation in InPedILD™, if the investigator’s benefit-risk assessment for the individual patient remains favourable.

    For patients who discontinued treatment permanently in 1199-0337 but are potentially eligible:

    All exclusion criteria for new patients are applicable with following additional exclusion criterion:
    21. Patients who experienced drug-related adverse events during parent trial leading to permanent study treatment discontinuation.
    Pour les nouveaux patients :

    1.ASAT et/ou ALAT >1,5 x LNS à la visite 1.
    2.Bilirubine >1,5 x LNS à la visite 1.
    3. eGFR) <30 mL/min/1,73 m2 calculée selon la formule de Schwartz à la visite 1.
    4.Patients atteints d’une maladie hépatique chronique sous-jacente (score de Child Pugh A, B et C) à la visite 1.
    5.Autres thérapies expérimentales reçues dans le mois ou équivalent à cinq demi-vies (selon le délai le plus court mais ≥ 1 semaine) précédent la visite 2, à l'exception du traitement expérimental reçu dans le cadre de l'essai InPedILD™.
    6.Hypertension artérielle pulmonaire significative définie par l’un des critères suivants :
    a) résultat clinique ou échocardiographique antérieur d’insuffisance cardiaque droite significative.
    b) antécédent de cathétérisation cardiaque droite montrant un index cardiaque ≤ 2 L/min/m2.
    c) HTPA nécessitant une thérapie parentérale avec époprosténol/tréprostinil.
    7.Selon l’avis de l’investigateur, d’autres anomalies pulmonaires cliniquement significatives.
    8.Pathologies cardiovasculaires, de type :
    a) hypertension artérielle sévère, non contrôlée sous traitement, dans les 6 mois précédant la visite 1.
    b) infarctus du myocarde dans les 6 mois précédant la visite 1.
    c) angor instable dans les 6 mois précédant la visite 1.
    9.Risque de saignement, de type :
    a) prédisposition génétique connue aux saignements.
    b) patient qui requiert une fibrinolyse, une anticoagulation thérapeutique à dose complète (par exemple avec des AVK, des inhibiteurs directs de la thrombine, de l’héparine, de l’hirudine) et des thérapies antiplaquettaires à dose élevée.
    c) antécédent d’hémorragie du système nerveux central dans les 12 mois précédant la visite 1.
    d) l’un des critères suivants dans les 3 mois précédant la visite 1 : - hémoptysie ou hématurie ;
    - hémorragie gastro-intestinale active ou ulcères gastro-intestinaux ;
    - blessure majeure ou chirurgie (selon le jugement de l’investigateur).
    e) l’un des paramètres de coagulation suivants lors de la visite 1 : - INR > 2 ;
    - prolongation du temps de prothrombine > 1,5 x LNS ;
    - prolongation du TCA > 1,5 x LNS.
    10.Antécédent d’évènement thrombotiques (y compris un accident vasculaire cérébral et un accident ischémique transitoire) dans les 12 mois précédant la visite 1.
    11. Hypersensibilité connue au traitement à l’étude ou à ses excipients (comme la lécithine de soja).
    12. Patients avec allergie documentée aux arachides ou au soja.
    13.Autre maladie pouvant interférer avec les procédures de l’essai, ou selon le jugement de l’investigateur pouvant interférer avec la participation à l’étude ou exposer le patient à un risque lors de sa participation à l’essai.
    14.Espérance de vie < 2,5 ans ayant pour cause toute maladie concomitante autre que la pneumopathie interstitielle (selon le jugement de l’investigateur).
    15.Patientes enceintes, allaitantes ou qui envisagent une grossesse au cours de l’étude.
    16.Patients incapables ou désireux de suivre les procédures de l’essai, y compris la prise du traitement à l’étude.
    17.Patients qui doivent ou souhaitent prendre tout traitement considéré comme susceptible d'interférer avec le bon déroulement de l'essai selon l'évaluation bénéfice-risque de l'investigateur pour chaque patient.
    18.Patients présentant un trouble de croissance diagnostiqué, tel qu’un déficit en hormone de croissance ou tout trouble génétique associé à une petite taille (comme par exemple un syndrome de Turner, de Noonan ou de Russel-Silver) et/ou traité par hormone de croissance dans les 6 mois précédant la visite 2. Les patients dont la petite taille est considérée par l’investigateur comme étant due à un traitement par glucocorticoïdes peuvent être inclus.
    19.Patient (masculin ou féminin) dont le poids est inférieur à 13,5 kg à la visite 1.

    Pour les patients ayant participé à l’essai InPedILD™ :
    Seuls les critères 11, 12, 13, 15, 16, 17 et 19 pour les nouveaux patients sont applicables avec le critère d’exclusion supplémentaire suivant :
    20. Patient non compliant dans l’essai InPedILDTM, concernant le traitement à l’étude ou les visites de l’essai, selon le jugement de l’investigateur.

    Les patients issus de l’essai InPedILDTM peuvent être éligibles même si d’autres critères d’exclusion ont été rencontrés au cours de la participation à l’essai InPedILDTM, si l’évaluation bénéfice/risque de l’investigateur pour le patient concerné reste favorable.

    Pour les patients qui ont arrêté définitivement le traitement dans l’essai InPedILD™ mais qui sont potentiellement éligibles :
    Tous les critères d’exclusion pour les nouveaux patients sont applicables, avec le critère d’exclusion supplémentaire suivant :
    21. Patients qui ont présenté des évènements indésirables liés au traitement à l’étude entrainant l’arrêt définitif du traitement.




    E.5 End points
    E.5.1Primary end point(s)
    1) The primary endpoint is the incidence of treatment emergent adverse events over the whole trial.
    1) Le critère de jugement principal est l’incidence des événements indésirables survenus pendant le traitement sur l’ensemble de l’essai.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1) Whole trial duration
    1) Toute la durée de l'essai.
    E.5.2Secondary end point(s)
    None
    Aucun
    E.5.2.1Timepoint(s) of evaluation of this end point
    None
    Aucun
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA18
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    Canada
    Mexico
    Russian Federation
    Ukraine
    United States
    Belgium
    Denmark
    Finland
    France
    Germany
    Hungary
    Italy
    Netherlands
    Norway
    Poland
    Portugal
    Spain
    United Kingdom
    Czechia
    Argentina
    Greece
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 60
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 18
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 38
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 4
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state4
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 30
    F.4.2.2In the whole clinical trial 60
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Aucun
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-01-05
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-12-21
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 20:45:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA